PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

British Journal of Haematology

Volumn 102, Issue 5, 1998, Pages 1376-1379

  Van Barren, N ^a,b   Chambost, H ^c,d   Ferrant, A ^e   Michaux, L ^e,f   Ikeda, H ^g   Millard, I ^h   Olive, D ^c   Boon, T ^a,b   Coulie, P G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c INSERM   (France)

^d TIMONE HOSPITAL   (France)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g Division of Cellular Signaling   (Japan)

^h Centre for Applied Molecular Technology   (Belgium)

Author keywords

Antigen; Chromosomal abnormalities; Cytolytic T lymphocyte; Immunotherapy; Leukaemia

Indexed keywords

TUMOR ANTIGEN;

ACUTE LEUKEMIA; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CHROMOSOME ABERRATION; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MELANOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ANTIGENS, NEOPLASM; CHROMOSOME ABERRATIONS; GENE EXPRESSION; HUMANS; LEUKEMIA; MELANOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; T-LYMPHOCYTES;

EID: 0031687558     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00982.x     Document Type: Article

References (17)

1. Bos, J.L. (1989) Ras oncogenes in human cancer: a review. Cancer Research, 49, 4682-4689.
2. Chambost, H., Brasseur, F., Coulie, P.G., De Plaen, E., Stoppa, A.M., Baume, D., Mannoni, P., Boon, T., Maraninchi, D. & Olive, D. (1993) A tumour-associated antigen expression in human haematological malignancies. British Journal of Haematology, 84, 524-526.
3. Coulie, P.G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M. & Boon, T. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 92, 7976-7980.
4. (+) T lymphocytes, generated by mutant p21ras (12val) peptide vaccination of a patient, recognize 12val dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. International Journal of Cancer, 72, 784-790.
5. Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De-Wolf-Peeters, C., Falini, B. & Gatter, K. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
6. Ikeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T. & Coulie, P.G. (1997) Cytolytic T cells expressing NK inhibitory receptor p58·2 recognize on a melanoma metastasis lacking HLA-Cw7 an antigen encoded by a gene which is preferentially expressed in tumors. Immunity, 6, 199-208.
7. Kannagi, M., Matsushita, S. & Harada, S. (1993) Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukaemia cells. International Journal of Cancer, 54, 582-588.
8. Lethé, B., van der Bruggen, P., Brasseur, F. & Boon, T. (1997) MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Research, 7, (Suppl. 2), S83-S88.
9. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. & van der Bruggen, P. (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. Journal of Experimental Medicine, 186, 785-793.
10. Molldrem, J., Dermime, S., Parker, K., Jiang, Y.Z., Mavroudis, D., Hensel, N., Fukushima, P. & Barrett, A.J. (1996) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase-3 preferentially lyse human myeloid leukemia cells. Blood, 88, 2450-2457.
11. Murray, R., Kurilla, M., Brooks, J., Thomas, W., Rowe, M., Kieff, E., & Rickinson, A. (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. Journal of Experimental Medicine, 176, 157-168.
12. Robbins, P., El-Gamil, M., Li, Y., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by infiltrating lymphocytes. Journal of Experimental Medicine. 183, 1185-1192.
13. Shichijo, S., Sagawa, K., Brasseur, F., Boon, T. & Itoh, K. (1996) MAGE-1 gene is expressed in T-cell leukaemia. International Journal of Cancer, 65, 709-710.
14. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood, 88, 3522-3527.
15. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S. & Boon, T. (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. Journal of Experimental Medicine, 182, 689-698.
16. Van den Eynde, B. & van der Bruggen, P. (1997) T cell defined tumor antigens. Current Opinion in Immunology, 9, 684-693.
17. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281-1284.